Oracle Corporation (ORCL) Stumbles but Deserves Forgiveness

Page 1 of 2

I asked recently if Oracle Corporation (NASDAQ:ORCL) can hold its momentum. After all, the stock had been on a considerable run of more than 40% since last year. Plus, with the recent acquisition of Acme Packet, Inc. (NASDAQ:APKT) , there seemed to be nothing standing in the way of the database giant from further gains. However, after disappointed third-quarter results, which sent the stock tumbling down 8%, I got my answer.

Are we getting carried away?
In my recent article, which previewed Oracle Corporation (NASDAQ:ORCL)’s earnings results, the Street missed the part where I warned investors of potential seasonality-related weaknesses in this quarter. I said:

We can make all of the predictions we want about earnings. Whether or not Oracle beats estimates or produces results that arrives in line with expectations, everything will hinge on how the company guides for the rest of the year and possibly fiscal 2014. I say this to caution investors to not be so focused on what the company reports this quarter.

Nevertheless, management guided for Q3 earnings per share of $0.64 to $0.68 — slightly higher than $0.62 per share earned a year ago. Revenue growth is projected to come in the area of 1% to 5% — ranging from $9.1 to $9.5 billion. Although these are not breathtaking projections, investors have to keep in mind that Oracle has not posted historically strong seasonal Q3 numbers.

The stock’s punishment is a gross overreaction. And as I’ve said before, it’s a mistake to judge a company like Oracle on a per-quarter basis. Given Oracle Corporation (NASDAQ:ORCL)’s recent moves into the enterprise and the cloud, the real story is about where the company is heading, not where it is today.

Is there legitimate cause for concern?
At first glance, I can see why investors got spooked. Aside from missing both top- and bottom-line estimates, the degree of the miss was pretty significant. With revenue arriving more than 4% below estimates, this was the company’s worst miss in almost two years. However, management didn’t seem all that concerned about the business. Sales execution, however, was another issue.

Revenue arrived at $8.9 billion, representing a 1% drop year over year and falling short of Street targets of $9.38 billion. Management said that the decline was due to a “lack of urgency” within its sales force, particularly from those that were newly hired. Still, it doesn’t help knowing that chief rival salesforce.com, inc. (NYSE:CRM) just posted sales of $835 million, which beat consensus estimates of $830 million.

However, this isn’t something that would concern me. For Oracle Corporation (NASDAQ:ORCL), the weak sales execution just means that revenue is being pushed out farther than expected. It’s not a signal of loss of market share. Again, I pointed out earlier that Q3 is typically Oracle’s slowest quarter. And investors should expect these sales delays to be closed in the Q4 report, a notion that management agreed with.

Besides, it didn’t affect profitability by much. Net income still arrived at $2.5 billion, or $0.52 per share. Excluding items, earnings rose to $0.65 per share. However, if investors should have a legitimate gripe about anything, it’s that software and cloud subscription revenue declined 2%. This is the barometer that tracks how well Oracle Corporation (NASDAQ:ORCL) is doing against salesforce.com and SAP in that all-important software-as-a-service, or SaaS, category.

Management has to do better here, because not only do software sales generate high margins, but they also provide long-term maintenance contracts, which is an important gauge of future profitability. So the 2% decline was glaring, especially since the company had forecasted growth of 3% to 13%. And when compared with Q2, during which Oracle Corporation (NASDAQ:ORCL) posted 17%, which (then) topped management’s own bullish projections, eyebrows have to be raised.

Time to regroup

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!